Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients

J. L. Murray, E. S. Kleinerman, J. E. Cunningham, J. R. Tatom, K. Andrejcio, J. Lepe-Zuniga, L. M. Lamki, M. G. Rosenblum, H. Frost, J. U. Gutterman, I. J. Fidler, I. H. Krakoff

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Twenty-eight evaluable patients with metastatic cancer refractory to standard therapy received escalating doses of muramyl tripeptide phosphatidylethanolamine (MTP-PE) (.05 and 12 mg/m2) in phosphatidylserine (PC):phosphatidylcholine (PS) liposomes (lipid:MTP-PE ratio 250:1). Liposomal MTP-PE (L-MTP-PE) was infused over 1 hour twice weekly; doses were escalated within individual patients every 3 weeks as tolerated for a total treatment duration of 9 weeks. Routine clinical laboratory parameters, acute phase reactants and various immunologic tests were monitored at various time points during treatment. Toxicity was moderate (≤ grade II) in 24 patients with chief side effects being chills (80% of patients), fever (70%), malaise (60%), and nausea (55%). In four patients L-MTP-PE treatment was deescalated due to severe malaise and recurrent fever higher than 38.8°C. The maximum-tolerated dose (MTD) was 6 mg/m2. Significant (P < .05) increases in WBC count, absolute granulocyte count, ceruloplasmin, β2-microglobulin, c-reactive protein, monocyte tumoricidal activity, and serum IL-1β were found. Significant decreases in serum cholesterol were also observed. Clearance of intravenously (iv)-infused technetium-99 (99mTc)-labeled liposomes containing MTP-PE in four patients was biphasic; gamma camera scans revealed uptake of radiolabel in liver, spleen, lung, nasopharynx, thyroid gland, and tumor (two patients). No objective tumor regression was seen. In view of its definite immunobiologic activity and lack of major toxicity, additional phase II and adjuvant trials of L-MTP-PE are warranted.

Original languageEnglish
Pages (from-to)1915-1925
Number of pages11
JournalJournal of Clinical Oncology
Volume7
Issue number12
Publication statusPublished - 1989

Fingerprint

Neoplasms
Liposomes
Fever
Chills
Immunologic Tests
Gamma Cameras
Ceruloplasmin
Maximum Tolerated Dose
Nasopharynx
Acute-Phase Proteins
Phosphatidylserines
Technetium
Therapeutics
mifamurtide
Serum
Phosphatidylcholines
Interleukin-1
Granulocytes
Nausea
Monocytes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Murray, J. L., Kleinerman, E. S., Cunningham, J. E., Tatom, J. R., Andrejcio, K., Lepe-Zuniga, J., ... Krakoff, I. H. (1989). Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. Journal of Clinical Oncology, 7(12), 1915-1925.

Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. / Murray, J. L.; Kleinerman, E. S.; Cunningham, J. E.; Tatom, J. R.; Andrejcio, K.; Lepe-Zuniga, J.; Lamki, L. M.; Rosenblum, M. G.; Frost, H.; Gutterman, J. U.; Fidler, I. J.; Krakoff, I. H.

In: Journal of Clinical Oncology, Vol. 7, No. 12, 1989, p. 1915-1925.

Research output: Contribution to journalArticle

Murray, JL, Kleinerman, ES, Cunningham, JE, Tatom, JR, Andrejcio, K, Lepe-Zuniga, J, Lamki, LM, Rosenblum, MG, Frost, H, Gutterman, JU, Fidler, IJ & Krakoff, IH 1989, 'Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients', Journal of Clinical Oncology, vol. 7, no. 12, pp. 1915-1925.
Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J et al. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. Journal of Clinical Oncology. 1989;7(12):1915-1925.
Murray, J. L. ; Kleinerman, E. S. ; Cunningham, J. E. ; Tatom, J. R. ; Andrejcio, K. ; Lepe-Zuniga, J. ; Lamki, L. M. ; Rosenblum, M. G. ; Frost, H. ; Gutterman, J. U. ; Fidler, I. J. ; Krakoff, I. H. / Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. In: Journal of Clinical Oncology. 1989 ; Vol. 7, No. 12. pp. 1915-1925.
@article{c6ab011b2433479cb2d933fa042b48bf,
title = "Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients",
abstract = "Twenty-eight evaluable patients with metastatic cancer refractory to standard therapy received escalating doses of muramyl tripeptide phosphatidylethanolamine (MTP-PE) (.05 and 12 mg/m2) in phosphatidylserine (PC):phosphatidylcholine (PS) liposomes (lipid:MTP-PE ratio 250:1). Liposomal MTP-PE (L-MTP-PE) was infused over 1 hour twice weekly; doses were escalated within individual patients every 3 weeks as tolerated for a total treatment duration of 9 weeks. Routine clinical laboratory parameters, acute phase reactants and various immunologic tests were monitored at various time points during treatment. Toxicity was moderate (≤ grade II) in 24 patients with chief side effects being chills (80{\%} of patients), fever (70{\%}), malaise (60{\%}), and nausea (55{\%}). In four patients L-MTP-PE treatment was deescalated due to severe malaise and recurrent fever higher than 38.8°C. The maximum-tolerated dose (MTD) was 6 mg/m2. Significant (P < .05) increases in WBC count, absolute granulocyte count, ceruloplasmin, β2-microglobulin, c-reactive protein, monocyte tumoricidal activity, and serum IL-1β were found. Significant decreases in serum cholesterol were also observed. Clearance of intravenously (iv)-infused technetium-99 (99mTc)-labeled liposomes containing MTP-PE in four patients was biphasic; gamma camera scans revealed uptake of radiolabel in liver, spleen, lung, nasopharynx, thyroid gland, and tumor (two patients). No objective tumor regression was seen. In view of its definite immunobiologic activity and lack of major toxicity, additional phase II and adjuvant trials of L-MTP-PE are warranted.",
author = "Murray, {J. L.} and Kleinerman, {E. S.} and Cunningham, {J. E.} and Tatom, {J. R.} and K. Andrejcio and J. Lepe-Zuniga and Lamki, {L. M.} and Rosenblum, {M. G.} and H. Frost and Gutterman, {J. U.} and Fidler, {I. J.} and Krakoff, {I. H.}",
year = "1989",
language = "English",
volume = "7",
pages = "1915--1925",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients

AU - Murray, J. L.

AU - Kleinerman, E. S.

AU - Cunningham, J. E.

AU - Tatom, J. R.

AU - Andrejcio, K.

AU - Lepe-Zuniga, J.

AU - Lamki, L. M.

AU - Rosenblum, M. G.

AU - Frost, H.

AU - Gutterman, J. U.

AU - Fidler, I. J.

AU - Krakoff, I. H.

PY - 1989

Y1 - 1989

N2 - Twenty-eight evaluable patients with metastatic cancer refractory to standard therapy received escalating doses of muramyl tripeptide phosphatidylethanolamine (MTP-PE) (.05 and 12 mg/m2) in phosphatidylserine (PC):phosphatidylcholine (PS) liposomes (lipid:MTP-PE ratio 250:1). Liposomal MTP-PE (L-MTP-PE) was infused over 1 hour twice weekly; doses were escalated within individual patients every 3 weeks as tolerated for a total treatment duration of 9 weeks. Routine clinical laboratory parameters, acute phase reactants and various immunologic tests were monitored at various time points during treatment. Toxicity was moderate (≤ grade II) in 24 patients with chief side effects being chills (80% of patients), fever (70%), malaise (60%), and nausea (55%). In four patients L-MTP-PE treatment was deescalated due to severe malaise and recurrent fever higher than 38.8°C. The maximum-tolerated dose (MTD) was 6 mg/m2. Significant (P < .05) increases in WBC count, absolute granulocyte count, ceruloplasmin, β2-microglobulin, c-reactive protein, monocyte tumoricidal activity, and serum IL-1β were found. Significant decreases in serum cholesterol were also observed. Clearance of intravenously (iv)-infused technetium-99 (99mTc)-labeled liposomes containing MTP-PE in four patients was biphasic; gamma camera scans revealed uptake of radiolabel in liver, spleen, lung, nasopharynx, thyroid gland, and tumor (two patients). No objective tumor regression was seen. In view of its definite immunobiologic activity and lack of major toxicity, additional phase II and adjuvant trials of L-MTP-PE are warranted.

AB - Twenty-eight evaluable patients with metastatic cancer refractory to standard therapy received escalating doses of muramyl tripeptide phosphatidylethanolamine (MTP-PE) (.05 and 12 mg/m2) in phosphatidylserine (PC):phosphatidylcholine (PS) liposomes (lipid:MTP-PE ratio 250:1). Liposomal MTP-PE (L-MTP-PE) was infused over 1 hour twice weekly; doses were escalated within individual patients every 3 weeks as tolerated for a total treatment duration of 9 weeks. Routine clinical laboratory parameters, acute phase reactants and various immunologic tests were monitored at various time points during treatment. Toxicity was moderate (≤ grade II) in 24 patients with chief side effects being chills (80% of patients), fever (70%), malaise (60%), and nausea (55%). In four patients L-MTP-PE treatment was deescalated due to severe malaise and recurrent fever higher than 38.8°C. The maximum-tolerated dose (MTD) was 6 mg/m2. Significant (P < .05) increases in WBC count, absolute granulocyte count, ceruloplasmin, β2-microglobulin, c-reactive protein, monocyte tumoricidal activity, and serum IL-1β were found. Significant decreases in serum cholesterol were also observed. Clearance of intravenously (iv)-infused technetium-99 (99mTc)-labeled liposomes containing MTP-PE in four patients was biphasic; gamma camera scans revealed uptake of radiolabel in liver, spleen, lung, nasopharynx, thyroid gland, and tumor (two patients). No objective tumor regression was seen. In view of its definite immunobiologic activity and lack of major toxicity, additional phase II and adjuvant trials of L-MTP-PE are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0024789583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024789583&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 1915

EP - 1925

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -